Minerva Neurosciences, Inc.
NERV
$1.67
-$0.055-3.19%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 13,505.31% | -97.80% | |||
| Gross Profit | -13,505.31% | 97.80% | |||
| SG&A Expenses | 2.44% | 2.55% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.56% | -30.44% | |||
| Operating Income | -3.56% | 30.44% | |||
| Income Before Tax | -118.98% | 373.43% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -118.98% | 373.43% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -118.98% | 373.43% | |||
| EBIT | -3.56% | 30.44% | |||
| EBITDA | -3.56% | 30.45% | |||
| EPS Basic | -118.98% | 373.43% | |||
| Normalized Basic EPS | -118.98% | 373.42% | |||
| EPS Diluted | -119.00% | 373.03% | |||
| Normalized Diluted EPS | -118.98% | 373.42% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||